1.
[Effect of Tongxinluo on endothelial function and hypersensitive C-reactive protein in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Ma, Q, Zhang, S, Ning, Y, Pu, X, Yu, G, Zheng, Z, Chen, X, Hu, K, Yang, T
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2009;(6):550-4
Abstract
OBJECTIVE To determine the effect of Tongxinluo on the endothelial function and hypersensitive C-reactive protein (hs-CRP) in acute coronary syndrome patients undergoing percutaneous coronary intervention(PCI). METHODS Thirty-three patients with unstable angina pectoris and 6 patients with acute myocardial infarction who underwent PCI for stenotic lesions of the coronary artery were enrolled. The patients were randomly assigned to a conventional group (n = 19) which took routine treatment or a tongxinluo group (n = 20) which took Tongxinluo(4 capsules once, 3 times per day) at the base of routine treatment after PCI. Nitric oxide synthase (NOS), nitric oxide (NO), endothelium-dependent vasodilation which was evaluated in the brachial artery flow mediated diameter(FMD) and hs-CRP were measured before the PCI and 24 hours and 3 months after the PCI. The correlation between NO and hs-CRP was analyzed. RESULTS NOS, NO, and FMD in the 2 groups 24 hours after the PCI were significantly lower than those before the PCI(P < 0.05), but hs- CRP obviously increased (P < 0.05). NOS, NO, and FMD 3 months after the PCI in the 2 groups were significantly higher than those before the PCI (P < 0.05 or P < 0.01), but hs-CRP obviously decreased (P < 0.01).All indexes mentioned above in the Tongxinluo group showed greater changes than those of the conventional group(P < 0.05). NO was negatively correlated with hs-CRP (r = -0.3219, P<0.01). CONCLUSION Tongxinluo capsules have obvious beneficial effect on endothelial function and anti-inflammation in acute coronary syndrome patients undergoing PCI, by directly acting on the endothelium and indirectly inhibiting inflammation.
2.
[Multicentric randomized double blinded clinical study of Yiqi Tongmai Oral Liquid against angina pectoris in patients with coronary heart disease].
Zhang, S, Song, YQ, Yue, W, Mao, XR, Ju, CX, Dong, MJ, Zheng, QL, Dai, XH, Li, ZY, Wang, SP
Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 2007;(4):383-91
Abstract
OBJECTIVE To study the efficacy and safety of Yiqi Tongmai Oral Liquid (YQTM), a traditional compound Chinese herbal medicine, in treating angina pectoris in patients with coronary heart disease. METHODS A multicentric, randomized, double blinded and paralleled controlled trial was conducted on 110 patients in trial group treated with YQTM, and 109 patients in control group treated with Shuxin Oral Liquid (SX). Cure and effective rates in both groups were evaluated. Frequency and duration of angina attack were counted and measured. Coronary angiography (CAG), electrocardiogram (ECG) and flat exercise test were taken in both groups. Blood lipid indexes, such as cholesterol (CH), triglyceride (TG), low-density lipoprotein (LDL), high density lipoprotein (HDL), were determined at pre- and post-treatment. The hemodynamic indexes, such as whole blood viscosity (J2), high-shear reduced viscosity (Eh), low-shear reduced viscosity (Ei), red cell aggregation index (Lb), red cell rigidity index (Rh), fibrinogen (Fb), blood sedimentation rate (BSR) and hematocrit (HCT), were determined at pre-and post-treatment. The indicated scores of symptoms and signs of traditional Chinese medicine (TCM) pattern, such as chest pain, chest constriction, breath shortness, palpitation, fatigue, dim complexion, spontaneous perspiration and tongue proper, tongue coating were evaluated in week 0, 1, 2, 3, 4 during the treatment course. The safety indexes, such as body temperature, pulse, respiration and blood pressure were observed. Routine tests of blood, urine and stool, hepatic function test and renal function test were taken at pre- and post-treatment. RESULTS There was no significant difference between the total effective rate of the trial group and that of the control group, which were 91.82% and 85.32%, respectively (P>0.05). Trial groups percentile of cure rate is significantly higher than that of the control group (P<0.01). The frequency and duration of angina attack, the positive ratio of CAG and flat exercise test of both groups were lowered, while the effect of the trial group on frequency and duration of angina attack was better. No significant difference was found in ECG features between the two groups (P>0.05). The levels of CH, TG and LDL of both groups were lowered significantly (P<0.05). The effect of lowering CH, TG and LDL of the trial group was stronger than that of the control group (P<0.05). The hemodynamic indexes, such as J2, Eh, Ei, Lb, Rh, Fb, BSR and HCT were improved significantly in both groups (P<0.05). The improvements of J2, Eh, Ei, Lb, Rh, Fb and SR in the trial group were greater than those of control group (P<0.05). The TCM symptoms and signs, such as chest pain, chest constriction, breath shortness, palpitation, fatigue, dim complexion, spontaneous perspiration were improved significantly in both groups (P<0.05). The improvements of chest constriction, palpitation, fatigue and spontaneous perspiration in the trial group were greater than those of the control group (P<0.05). The total indicated score of TCM symptoms and signs was lowered more significantly than that of the control group (P<0.01). No significant changes were found at pre- and post-treatment in safety indexes, such as routine tests for blood, urine and stool, hepatic function test and renal function test. There was no significant difference in safety features of both groups (P>0.05). CONCLUSION Yiqi Tongmai Oral Liquid bears good therapeutic effect on angina pectoris without adverse reaction, and is superior to Shuxin Oral Liquid. Yiqi Tongmai Oral Liquid is a new effective and safe medicine for the treatment of angina pectoris in patients with coronary heart disease.
3.
[Dynamic changes of serum pro-inflammatory cytokines and anti-inflammatory cytokines in patients with acute infection and the effect of Chinese herbal medicine intervention].
Qi, W, Ren, A, Zhang, S
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2000;(11):824-7
Abstract
OBJECTIVE To study the dynamic changes of serum pro-inflammatory cytokines and anti-inflammatory cytokines in patients with acute infection and to explore the effect of 912 compound, a Chinese herbal preparation for intervention. METHODS Forty patients with acute infection were randomly divided into 2 groups, 20 in the 912 group and 20 in the control group, and the levels of plasma endotoxin (lipopolysaccharide, LPS), serum pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) and anti-inflammatory cytokines, including soluble TNF-RI, IL-4 and IL-10 were measured before and after treatment by using limulus reagent stroma azo-colored quantitative method and enzyme-linked immunosorbent assay (ELISA). RESULTS The level of LPS increased at the early stage of acute infection, the levels of pro- and anti-inflammatory cytokines were all elevated in various degrees, particularly obvious in IL-6, sTNF-RI, IL-4 and IL-10 and the elevations of the two were basically parallel. The TNF alpha, IL-6 and sTNF-RI were positively related with APACHE III scoring. The levels of LPS and inflammatory cytokines reduced to a different extent in accord with the improvement of condition after treatment, the levels of LPS, TNF alpha, IL-6 and IL-10 lowered more significantly in the 912 group than those in the control group (P < 0.05). CONCLUSIONS LPS, pro-inflammatory and anti-inflammatory cytokines play important roles in the acute infection process, they were important indexes for evaluating severity of infectious diseases. The Chinese herbal preparation 912 compound could reduce the blood levels of LPS, TNF alpha, IL-6, IL-10 and prevent the decrease of sTNF-RI so as to promote the recovery of patients.